Murphy & Mullick Capital Management Corp Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Murphy & Mullick Capital Management Corp bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 444 shares of the biopharmaceutical company's stock, valued at approximately $316,000.

A number of other hedge funds have also recently made changes to their positions in REGN. Intact Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $356,000. Principal Financial Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Golden State Equity Partners boosted its position in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after acquiring an additional 1,272 shares during the last quarter. Fagan Associates Inc. grew its holdings in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the period. Finally, ABC Arbitrage SA bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $1,510,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $1.53 during trading hours on Friday, hitting $637.36. The company had a trading volume of 805,912 shares, compared to its average volume of 673,409. The firm has a 50 day simple moving average of $683.88 and a 200 day simple moving average of $800.34. Regeneron Pharmaceuticals, Inc. has a 52 week low of $629.02 and a 52 week high of $1,211.20. The firm has a market capitalization of $69.68 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Bernstein Bank dropped their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Bank of America restated an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Finally, Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.